Botulinum toxin type B

Dermatologic Surgery

Volumn 29, Issue 4, 2003, Pages 348-351

  Sadick, Neil S ^a,b   Matarasso, Seth L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ESTHETICS; FACE DEFORMITY; HUMAN; MUSCLE WEAKNESS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; XEROSTOMIA;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; HUMANS; RHYTIDOPLASTY;

EID: 0037387191     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2002.29083.x     Document Type: Article

References (12)

1. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001;20:127-36.
2. Johnson EA, Goodnough MC. Preparation and properties of botulinum toxin for medical use. In Tsui JKC, Calne DB, eds. Handbook of Dystonia. New York: Marcel Dekker, 1995:346-65.
3. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000;55(Suppl 5):S23-8.
4. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of Neurobloc™ (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-46.
5. Brin M, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc™ (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-8.
6. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
7. Sadick NS. Botulinum toxin type B (Myobloc) for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 2002;28:817-21.
8. Sadick NS, Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 units for the treatment of glabellar wrinkles. Dermatol Surg, in press.
9. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997;49:189-94.
10. Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002;4:15-8.
11. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (Myobloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 2002;126:459-67.
12. Spencer JM, Gordon M, Goldberg Botulinum B treatment of the glabellar and frontalis regions: a dose-response analysis. J Cosmet Laser Ther 2002;4:19-23.